DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting
Châtillon, France, June 11, 2025
DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting
Shareholders approved all proposed resolutions
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the 'Company'), held its Combined General Meeting (the 'General Meeting'). The General Meeting was chaired by Michel de Rosen, Chairman of the Company.
The Company's shareholders approved all resolutions submitted by the Board of Directors. The resolutions and the voting results are posted on the Investors/Annual General Meetings section of the Company's website: https://dbv-technologies.com/events/2025-annual-general-meeting/.
About DBV TechnologiesDBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary technology platform, Viaskin™, to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT™), the Viaskin platform is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual's underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin's immune tolerizing properties. DBV is committed to transforming the care of food allergic people. The Company's food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company's ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company's ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309).
For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.
Viaskin and EPIT are trademarks of DBV Technologies.
Investor Contact Katie MatthewsDBV Technologieskatie.matthews@dbv-technologies.com
Media ContactAngela Marcucci DBV Technologiesangela.marcucci@dbv-technologies.com
Attachment
PDF VersionFehler beim Abrufen der Daten
Melden Sie sich an, um Ihr Portfolio aufzurufen.
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Fehler beim Abrufen der Daten
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives
Updated data from DeFianCe study continue to demonstrate statistically significant improvements in PFS among the DKK1-high, VEGF-naïve and liver metastasis subgroups Board of Directors has initiated process to explore strategic alternatives to maximize shareholder value CAMBRIDGE, Mass., June 23, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported updated results from Part B of the DeFianCe study (NCT05480306), a Phase 2 study of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in combination with bevacizumab and chemotherapy (Sirexatamab Arm) compared to bevacizumab and chemotherapy (Control Arm) in patients with advanced microsatellite stable (MSS) colorectal cancer (CRC) who have received one prior systemic therapy for advanced disease. Due to the Company's financial position, Leap's Board of Directors is taking further steps to preserve capital and has initiated a process to explore strategic options to preserve and maximize shareholder value. "Sirexatamab demonstrated a statistically significant benefit in patients with high levels of DKK1, no prior exposure to anti-VEGF therapy, or liver metastasis, with a positive trend on ORR and PFS in the full second-line CRC population. With the additional patient follow-up, we believe that the objectives of the DeFianCe study have been achieved. On behalf of everyone at Leap, I thank all the patients and physicians who have participated in our sirexatamab clinical trials," said Douglas E. Onsi, President and Chief Executive Officer of Leap. "However, due to current market conditions, we have decided to wind-down the DeFianCe clinical trial and further reduce internal expenses. In parallel, we have initiated a review of the full range of strategic alternatives to maximize shareholder value." DeFianCe Study Update In the updated analysis as of May 22, 2025, sirexatamab demonstrated a positive trend on overall response rate (ORR), by investigator assessment (IA) and blinded independent central review (BICR), and progression-free survival (PFS) in the full second-line CRC population, driven by the statistically significant benefit in patients with high levels of DKK1, no prior exposure to anti-VEGF therapy, or liver metastasis. Across the intent-to-treat population (n=188):Sirexatamab Arm (n=94) Control Arm (n=94)Median PFS 9.2 months 8.31 months HR 0.84 95% CI: 0.57, 1.22 p = 0.1749 ORR by IA 35.1 % 26.6 % p = 0.1009 ORR by BICR 33.0 % 20.2 % P = 0.0203 Remaining on study drug 21 15In patients with high DKK1 levels (upper quartile, n=44):Sirexatamab Arm (n=25) Control Arm (n=19)Median PFS 9.36 months 5.88 months HR 0.47 95% CI: 0.22, 1.01 p = 0.0237 ORR by IA 44.0 % 15.8 % p = 0.0149 ORR by BICR 40.0 % 15.8 % p = 0.0301 Median OS Not Yet Reached 9.66 months HR 0.19 95% CI: 0.05, 0.73 p = 0.0037 Remaining on study drug 7 1In patients with DKK1 levels above the median (upper median, n=88):Sirexatamab Arm (n=50) Control Arm (n=38)Median PFS 9.03 months 7.23 months HR 0.56 95% CI: 0.33, 0.94 p = 0.0146 ORR by IA 38.0 % 23.7 % p = 0.0706 ORR by BICR 40.0 % 15.8 % p = 0.0039 Median OS Not Yet Reached 14.39 months HR 0.48 95% CI: 0.2, 1.16 p = 0.0475 Remaining on study drug 12 3In patients who had not received prior anti-VEGF therapy (n=95):Sirexatamab Arm (n=49) Control Arm (n=46)Median PFS 11.2 months 8.34 months HR 0.61 95% CI: 0.35, 1.06 p = 0.0383 ORR by IA 55.1 % 32.6 % p = 0.0116 ORR by BICR 44.9 % 26.1 % p = 0.0252 Median OS Not Yet Reached Not Yet Reached HR 0.47 95% CI: 0.14, 1.6 p = 0.1069 Remaining on study drug 15 5In patients with liver metastases (n=138):Sirexatamab Arm (n=73) Control Arm (n=65)Median PFS 9.03 months 7.26 months HR 0.7 95% CI: 0.46, 1.06 p = 0.0443 ORR by IA 37.0 % 27.7 % p = 0.1203 ORR by BICR 30.1 % 24.6 % p = 0.233 Median OS Not Yet Reached 15.74 HR 0.69 95% CI: 0.33, 1.43 p = 0.1584 Remaining on study drug 14 6Corporate Update Leap is taking additional steps to reduce spending and preserve capital. Over the next two months as the DeFianCe study completes, the Company will implement a workforce reduction of approximately 75%. The total cash payments and costs related to this reduction in force, including severance payments, are estimated to be approximately $3.2 million. The majority of these costs will be recognized in the third quarter of 2025. The Company's cash and cash equivalents totaled $32.7 million as of March 31, 2025. Leap has initiated a process to explore strategic alternatives to preserve and maximize shareholder value, including leveraging its cash balance and exploring potential sale or partnership opportunities for sirexatamab and FL-501. The Company's Board of Directors has approved the engagement of Raymond James & Associates, Inc. to serve as exclusive financial advisor to assist in the strategic evaluation process. About Leap TherapeuticLeap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. Sirexatamab is being studied in patients with colorectal cancer. Leap's pipeline also includes FL-501, a humanized monoclonal antibody targeting the growth and differentiation factor 15 (GDF-15) protein, in preclinical development. For more information about Leap Therapeutics, visit or view our public filings with the SEC that are available via EDGAR at or via FORWARD-LOOKING STATEMENTSThis press release contains forward-looking statements within the meaning of the federal securities laws. Such statements are based upon current plans, estimates and expectations of the management of Leap that are subject to various risks and uncertainties that could cause actual results to differ materially from such statements. The inclusion of forward-looking statements should not be regarded as a representation that such plans, estimates and expectations will be achieved. Words such as "anticipate," "expect," "project," "intend," "believe," "may," "will," "should," "plan," "could," "continue," "target," "contemplate," "estimate," "forecast," "guidance," "predict," "possible," "potential," "pursue," "likely," and words and terms of similar substance used in connection with any discussion of future plans, actions or events identify forward-looking statements. All statements, other than historical facts, including statements regarding the potential safety, efficacy, and regulatory and clinical progress of Leap's product candidates, including sirexatamab and FL-501; Leap's intention to implement a workforce reduction of approximately 75%, reduce clinical and operational activities, reduce spending and conserve cash, explore strategic alternatives to preserve and maximize shareholder value, including by leveraging its cash balance and potentially selling or partnering sirexatamab or FL-501; and any assumptions underlying any of the foregoing, are forward-looking statements. Important factors that could cause actual results to differ materially from Leap's plans, estimates or expectations could include, but are not limited to: (i) Leap's ability to successfully sell or enter into partnerships for sirexatamab or FL-501; (ii) the cost and timeline to complete the DeFianCe Study and wind-down clinical operations; (iii) any regulatory feedback that Leap may receive from U.S. Food and Drug Administration (FDA) or equivalent foreign regulatory agency or from site institutional review boards; (iv) the magnitude, timing and costs associated with the implementation of a workforce reduction; and (v) the availability of strategic alternatives would preserve or generate any shareholder value. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Leap may not actually achieve the forecasts disclosed in such forward-looking statements, and you should not place undue reliance on such forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to those set forth under the caption "Risk Factors" in Leap's most recent Annual Report on Form 10-K filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in its subsequent filings with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Neither Leap, nor any of its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing Leap's views as of any date subsequent to the date hereof. CONTACT: Douglas E. OnsiPresident & Chief Executive OfficerLeap Therapeutics, Inc.617-714-0360donsi@ Matthew DeYoungInvestor RelationsArgot Partners212-600-1902leap@ View original content to download multimedia: SOURCE Leap Therapeutics, Inc.
Yahoo
an hour ago
- Yahoo
Chesapeake Gold Announces Addition of Paul West-Sells and Jeff Stieber to the Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - June 23, 2025) - Chesapeake Gold Corp. (TSXV: CKG) (OTCQX: CHPGF) ("Chesapeake" or the "Company") is pleased to announce the recent election of Mr. Paul West-Sells to the Board of Directors of the Company (the "Board of Directors") at the Company's annual general meeting of shareholders held on June 18, 2025 (the "Meeting"), together with the returning incumbent directors P. Randy Reifel, Randy Buffington, Doug Flegg, Lian Li, and John Perston. Mr. West-Sells has more than 25 years of experience in the mining industry and held executive management and senior metallurgist roles for numerous public companies. Mr. West-Sells served as Chief Executive Officer and Chief Operating Officer of Western Copper and Gold Corporation. Prior thereto, Mr. West-Sells was a Senior Metallurgist at Barrick, Placer Dome and BHP Minerals. Mr. West-Sells holds a Ph.D. in Metals and Materials Engineering from the University of British Columbia and continues to lecture at the University of British Columbia as an Adjunct Professor in Materials Engineering. The Company is also pleased to announce the appointment of Mr. Jeff Stieber to the Board of Directors, effective June 20, 2025. Mr. Stieber brings 19 years of finance, accounting, strategy, and transaction experience to the Company, having served as a senior executive officer with Hycroft Mining, Klondex Mines, Tahoe Resources, White Pine Precious Metals, and Bendito Resources. He has experience across all stages of the mining project lifecycle, from guiding exploration-stage projects to advancing development assets into production and cash flow generation. Mr. Stieber is a Certified Public Accountant in the State of Nevada and a Certified Financial Modeling & Valuation Analyst. Concurrently, the Company also advises that long-time director Chris Falck has decided to retire to pursue other opportunities and be closer to family. Mr. Falck will continue to serve as an advisor, where his vast knowledge will be leveraged. P. Randy Reifel, Executive Chairman, commented, "On behalf of the Board, I am excited to welcome both Paul and Jeff to Chesapeake's team. Paul and Jeff bring a diversified wealth of experience and I look forward to their contributions in achieving our corporate objectives and milestones. I also sincerely thank Chris Falck for his years of dedication and commitment to the Company. Chris provided valuable insight and vital contributions as Lead Director and as a member of Board Committees during his tenure." For Further Information: For more information on Chesapeake, its Metates and Lucy Projects or proprietary oxidative leach technology, please visit our website at or contact Jean-Paul Tsotsos at invest@ or +1 778 731 1362. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. About Chesapeake Chesapeake Gold Corp's flagship asset is the Metates Project ("Metates") located in Durango State, Mexico. Metates hosts one of the largest undeveloped gold-silver deposits in the Americas1 with over 16.77 million ounces of gold at 0.57 grams per tonne (g/t) and 423.2 million ounces of silver at 14.3 g/t within 921.2 million tonnes in the Measured and Indicated Mineral Resource category and a further 2.13 million ounces of gold at 0.47 g/t and 59.0 million ounces of silver at 13.2 g/t within 139.5 million tonnes in the Inferred Mineral Resource category. See the technical report titled "Metates Sulphide Heap Leach Project Phase I" dated January 13, 2023, and news release dated February 22, 2023. 1 Mexico's biggest undeveloped gold deposits. Bnamericas. Published Tuesday, November 24, 2020. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
an hour ago
- Business Wire
Regis Corporation Announces Leadership Transition
MINNEAPOLIS--(BUSINESS WIRE)-- Regis Corporation (NasdaqGM: RGS), a leader in the haircare industry, today announced that Matthew Doctor has made the decision to step down from his roles as President, Chief Executive Officer and Director of the company effective June 30, 2025. The Board of Directors has appointed Jim Lain, current EVP Brand Operations – Supercuts and Cost Cutters, to serve as interim President and CEO while the company conducts a comprehensive search for a permanent successor. 'On behalf of the Board and everyone at Regis, I want to express our deepest gratitude to Matt for his leadership and steadfast dedication to the success of Regis,' said Mike Merriman, Chairman of the Board. 'Matt initially joined the company in a strategic role and quickly proved to be a transformative leader. He has been instrumental in shaping the company's direction, stabilizing operations, restoring profitability and strengthening our financial position. Thanks to Matt's leadership, the company is on solid financial footing and well-positioned for long-term growth. We are appreciative of his work and wish him continued success in his future endeavors. The Board looks forward to working with Jim and the executive team during this transition as we identify the next leader for this stage of the company's transformation.' 'It has been an honor and a privilege to lead Regis and work alongside such an exceptional and dedicated team,' said Matthew Doctor. 'After thoughtful consideration, I made the decision that now is the right time for me to explore other opportunities upon delivering another year of results and progress. Over the past four and half years that I have been at Regis, we have navigated meaningful change and established a strong foundation for reigniting growth. I am incredibly proud of everything we have accomplished, from improving operational efficiencies and completing a complex refinancing, to acquiring the portfolio of Alline salons. Our recent performance reflects both the strength of our strategy and the commitment of our teams. With the business on solid footing and momentum continuing to build, I believe this is a natural time to pass the baton to the next leader to drive further growth with the incredibly dedicated, passionate Regis team and franchisees. 'As I step down, I reflect on where we are - Regis is built on a strong, interconnected foundation that ensures continuity and progress. The outlook, priorities, and initiatives we outlined in our last earnings call remain firmly in place, supported by a collaborative effort across our leadership team, management, Board of Directors, and our retained consultancy at Forum3, who have been invaluable partners since January. Forum3 is led by Adam Brotman, who is one of the world's leading customer loyalty and engagement experts with over 25 years of experience leading major tech and consumer brands, including his role as Starbucks' inaugural Chief Digital Officer and EVP of Global Retail Operations. The progress we have made has always been the result of a team effort—one that includes the dedication of our employees and the support of our external partners. Our strategy is clear and focused: optimizing and growing the company-owned salon portfolio and advancing the transformation of the Supercuts brand. With this foundation in place, Regis is well-positioned to thrive, adapt, and create long-term value for all stakeholders. I am excited to watch the company continue to grow and succeed in the years ahead.' Succession Planning and Interim Leadership The Board has formed a Succession Planning Committee led by director Susan Lintonsmith and has engaged a leading executive search firm to help identify the next CEO, which will include both internal and external candidates. In the interim, Jim Lain, current EVP Brand Operations – Supercuts and Cost Cutters, will work closely with the executive team and Board to ensure a seamless transition and continued execution of the company's strategic priorities. To ensure a smooth transition, Matt Doctor will be staying on in a support role until September 1, 2025. Mr. Lain joined Regis in 2013, bringing with him more than 30 years of operations leadership experience. Since then, he has spearheaded initiatives that drove operational excellence and enhanced the performance of iconic brands including Supercuts, SmartStyle, Cost Cutters, First Choice Haircutters, Roosters and other legacy names within the Regis portfolio. Prior to Regis, Jim made significant contributions at Gap Inc., where he served as Vice President of Operations for Gap Specialty Stores in the U.S. and Canada. In this role, he was responsible for steering a $2.5 billion business across 750 stores, enhancing operational efficiency and driving growth in a highly competitive market. Prior to his experience with Gap, Jim was Vice President of Operations at Galyan's Trading Company Inc. / Dick's Sporting Goods and held several field management positions at Target Stores Inc. Preliminary Quarter-to-Date Same Store Sales Results for Fourth Quarter The company reports positive preliminary quarter-to-date same-store sales growth of 3.0% for Supercuts and 1.3% on a consolidated basis for the first two months of the fourth quarter of fiscal 2025 as compared with the same periods last year. Month-to-date same-store-sales through June 15, 2025 for Supercuts and Regis Consolidated are also positive as compared with the same period last year. Quarter-to-date operating expenses have remained consistent with the third quarter of fiscal 2025. About Regis Corporation Regis Corporation (NasdaqGM:RGS) is a leader in the haircare industry. As of March 31, 2025, the Company franchised or owned 4,087 locations. Regis' franchised and corporate locations operate under concepts such as Supercuts ®, SmartStyle ®, Cost Cutters ®, Roosters ®, and First Choice Haircutters ®. For additional information about the Company, including a reconciliation of certain non-GAAP financial information and certain supplemental financial information, please visit the Investor Relations section of the corporate website at Preliminary Unaudited Results This press release includes preliminary, unaudited same-store-sales and expense trends for the quarter-to-date of the fourth quarter of fiscal 2025, which represent the most current information available to Company management. The Company's actual results may differ from these preliminary financial results, including due to the completion of its financial closing procedures and final adjustments. This press release contains or may contain 'forward-looking statements' within the meaning of the federal securities laws, including statements concerning anticipated future events and expectations that are not historical facts. These forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements in this document reflect management's best judgment at the time they are made, but all such statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed in or implied by the statements herein. Such forward-looking statements are often identified herein by use of words including, but not limited to, 'may,' 'will,' 'believe,' 'project,' 'forecast,' 'expect,' 'estimate,' 'anticipate,' and 'plan.' In addition, the following factors could affect the Company's actual results and cause such results to differ materially from those expressed in forward-looking statements. These factors include a potential material adverse impact on our business and results of operations as a result of changes in consumer shopping trends and changes in manufacturer distribution channels; laws and regulations could require us to modify current business practices and incur increased costs including increases in minimum wages; changes in general economic environment; changes in consumer tastes, hair product innovation, fashion trends and consumer spending patterns; compliance with Nasdaq listing requirements; our ability to realize the anticipated benefits of the Alline Acquisition; reliance on franchise royalties and overall success of our franchisees' salons; our salons' dependence on a third-party supplier agreement for merchandise; our and our franchisees' ability to attract, train and retain talented stylists and salon leaders; the success of our franchisees, which operate independently; data security and privacy compliance and our ability to manage cyber threats and protect the security of potentially sensitive information about our guests, franchisees, employees, vendors or Company information; the ability of the Company to maintain a satisfactory relationship with Walmart; marketing efforts to drive traffic to our franchisees' salons; our ability to maintain and enhance the value of our brands; reliance on legacy information technology systems; reliance on external vendors; the use of social media; the effectiveness of our enterprise risk management program; our ability to minimize risks associated with owning and operating additional salons; ability to generate sufficient cash flow to satisfy our debt service obligations; compliance with covenants in our financing arrangement; premature termination of agreements with our franchisees; the continued ability of the Company to implement cost reduction initiatives and achieve expected cost savings; continued ability to compete in our business markets; potential liabilities related to the employee retention credit received by Alline; changes in trade policies, treaties, tariffs and customs duties and taxes; reliance on our management team and other key personnel; the continued ability to maintain an effective system of internal control over financial reporting; changes in tax exposure; the ability of our Tax Preservation Plan to protect the future availability of the Company's tax assets; potential litigation and other legal or regulatory proceedings; reliance on our management team and other key employees, including successfully recruiting a new chief executive officer as well as retaining our employees during this process, or other factors not listed above. Additional information concerning potential factors that could affect future financial results is set forth under Item 1A on Form 10-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. However, your attention is directed to any further disclosures made in our subsequent annual and periodic reports filed or furnished with the SEC on Forms 10-K, 10-Q and 8-K and Proxy Statements on Schedule 14A.
